Compare Gilead Sciences, Inc. (GILD) vs TeraWulf Inc (WULF) Price & Performance

Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.

The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.

WULF trades at $18.26, down 5.92% in the last 24 hours, with a bearish technical signal. The company reported a net loss of $661.42 million on $168.46 million revenue in 2025, with negative profitability metrics. However, sentiment is buoyed by a landmark 20-year, $19 billion AI infrastructure deal with Anthropic, positioning TeraWulf in the high-demand data center space. Analyst consensus remains strongly bullish with a $36.00 price target.

The outlook hinges on successful execution of the Anthropic partnership, offering significant revenue potential but requiring substantial capital expenditure. High valuation ratios and persistent losses present risks, yet Wall Street's unanimous buy rating reflects confidence in the AI infrastructure growth story. Investors face volatility from execution risks and sector sentiment shifts.